Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)
GAMPENRIEDER, S., DEZENTJE, V., LAMBERTINI, M., DE NONNEVILLE, A., MARHOLD, M., LE DU, F., SERRANO, C., COSTA, D., BLONDEAUX, E., DEL MASTRO, L., BERTUCCI, F., GONCALVES, A., BARTSCH, R., DELEUZE, A., SALGADO, A., VITORINO, M., TINCHON, C., PECEN, Ladislav, RINNERTHALER, G., GREIL, R. Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT). Annals of Oncology. 2022, 33(Suppl. 3), S208-S208. ISSN 0923-7534. E-ISSN 1569-8041 Dostupné z: doi:10.1016/j.annonc.2022.03.196
